Latest News and Press Releases

-Up to 6 patients to be enrolled in the second cohort, initial data expected in fourth quarter 2019- -Oral presentation at the Annual Meeting of the American Society of Gene and Cell Therapy- BASEL,...

-Details from ongoing SUNRISE-PD Phase 2 trial of AXO-Lenti-PD and the AXO-AAV-GM2 program to be featured in oral presentations- -Preclinical data from AXO-AAV-GM1 program to be highlighted in poster...

- Closing of $40 million financing with participation from leading shareholders - - 1-for-8 reverse share split expected in May 2019 - BASEL, Switzerland, April 04, 2019 (GLOBE NEWSWIRE) --...

-R&D Day featuring leading physicians and scientists in Parkinson’s disease, GM1 gangliosidosis and GM2 gangliosidosis (Tay-Sachs disease) will be webcast today at 8:30a.m. ET from New York- ...

NEW YORK and BASEL, Switzerland, March 14, 2019 (GLOBE NEWSWIRE) -- Axovant Sciences (Nasdaq: AXGT) ("Axovant") today announced the pricing of its underwritten public offering of 26,666,667 of its...

NEW YORK and BASEL, Switzerland, March 13, 2019 (GLOBE NEWSWIRE) -- Axovant Sciences (Nasdaq: AXGT) ("Axovant") today announced that it has commenced an underwritten public offering of its common...

25-point (42%) mean improvement in the UPDRS Part III (motor) OFF score, with individual patient improvements of 14-points and 36-points respectivelyBenefit seen across all UPDRS OFF subscales at 3...

Generally well-tolerated with no serious adverse events in a 30-month-old patient with advanced infantile Tay-Sachs diseaseStable clinical condition from baseline to month 3 without deterioration on...

NEW YORK and BASEL, Switzerland, March 04, 2019 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today announced that Pavan...

NEW YORK and BASEL, Switzerland, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today announced that it will host...